Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression

The overall aim of this proof-of-concept trial is to investigate the effect of an orally administered glycan on the modulation of the dysregulation of host-microbiome interactions and its effect on the mucosal immune response. Post-operative Crohn's Disease patients will be used as a representative model to mimic the immunopathogenic pathway of health-to-disease transition. Changes in gut glycocalyx seem to be a primary event involved in the disruption of the interaction between the microbiota and the host immune system. Thus, this study aims to assess the effect of the modulation of the glycome on the microbial and immunological changes that contribute to disease development.

NCT Number	NCT06727253
Lead Sponsor	GLSMED Learning Health S.A.
Conditions	Crohn Disease (CD)
Enrollment	30 participants
Start Date	2025-05-26
Primary Completion	2028-06-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-05